Company intelligence / Profile preview

age1

San Francisco, California, United Statesage1.com ↗

Ownership: Private
Development stage: Other

Overview

age1 is a venture capital firm specializing in funding and supporting early-stage longevity biotech startups developing therapeutics, tools, and technologies to extend healthy lifespan. It was launched in 2023 as the next chapter of The Longevity Fund’s mission, co-founded by Laura Deming and Dr. Alex Colville. The team has backed several notable longevity-focused biotechs that have reached IPO or clinical translation.

Industry: Investors

Partnerships

Strategic relationships with their funded startups and provide regulatory guidance from industry experts.

Beyond the preview

Go deeper on age1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on age1.

Explore the full profile